Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California at Los Angeles (ucla )
Los Angeles, California, United States
- Ucsf-Mount Zion
San Francisco, California, United States
- University of California San Francisco Medical Center-Parnassus
San Francisco, California, United States
- Adult Brain Tumor Consortium
Baltimore, Maryland, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital
Charlestown, Massachusetts, United States
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
- University of Pittsburgh
Pittsburgh, Pennsylvania, United States
- M D Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2008
- Primary completion
- 30 Jun 2013
- Completion
- 31 Dec 2013
- Last update posted
- 30 May 2014
- Registered enrollment
- 61
- Registry id
- NCT00650923
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.